This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Near-Perfect CPI Report Brings Pre-Markets Near Breakeven
by Mark Vickery
Pre-market futures had been wallowing in negative territory ahead of this print, but are now pushing toward breakeven at this hour.
NVDANegative Net Change WENPositive Net Change AAPPositive Net Change MRNAPositive Net Change
biotechnology consumer-discretionary earnings inflation
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
by Zacks Equity Research
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
NVSPositive Net Change ALKSNegative Net Change BAYRYPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.
REGNPositive Net Change ALKSNegative Net Change RARENegative Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
by Zacks Equity Research
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
ALNYPositive Net Change NVSPositive Net Change RHHBYNegative Net Change ALKSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Arrow Electronics (ARW) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ARWPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
by Ekta Bagri
Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
ZTS stock rises after Q4 earnings and revenues top estimates, as strong international growth and upbeat 2026 guidance offset U.S. softness.
ALKSNegative Net Change EXELPositive Net Change ZTSPositive Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
by Zacks Equity Research
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?
by Shaun Pruitt
Biotech leader Gilead Sciences (GILD) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.
GILDPositive Net Change
biotechnology dividend-investing dividends earnings investing large-cap medical pharmaceuticals
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales
by Zacks Equity Research
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.
GSKPositive Net Change GILDPositive Net Change RCUSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals